Premium
Protection against doxorubicin‐induced alopecia in rats by liposome‐entrapped monoclonal antibodies
Author(s) -
Balsari Andrea L.,
Morelli Daniele,
Ménard Sylvie,
Veronesi Umberto,
Colnaghi Maria I.
Publication year - 1994
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.8.2.8119493
Subject(s) - monoclonal antibody , liposome , doxorubicin , medicine , pharmacology , antibody , chemistry , immunology , chemotherapy , biochemistry
Alopecia is a common side effect of several anti‐cancer drugs, including doxorubicin. Based on our recent observation that a monoclonal antibody (MAD11) directed against this anthracycline inhibits the systemic toxic effect of the drug in mice, we investigated the possibility that MAD11 administered topically might protect against doxorubicin‐induced alopecia. In 31 of 45 young rats treated intraperitoneally with doxorubicin, alopecia was completely prevented by topical treatment of the skin with liposome‐incorporated anti‐doxorubicin monoclonal antibody. This type of treatment might find relevance in preventing anthracycline‐induced alopecia in cancer patients. Our findings also provide the first demonstration that liposome‐entrapped monoclonal antibodies are capable of penetrating the stratum corneum of the skin without losing their function.—Balsari, A. L., Morelli, D., Ménard, S., Veronesi, U., Colnaghi, M. I. Protection against doxorubicin‐induced alopecia in rats by liposome‐entrapped monoclonal antibodies. FASEB J. 8: 226‐230; 1994.